Patients undergoing heart surgery might see better outcomes and shorter hospital stays if they opt for intraoperative autologous blood donation, according to research out of New York.

An extended analysis of the ODYSSEY OUTCOMES trial has confirmed alirocumab, a PCSK9 inhibitor that hit the medical market in 2015, reduces a patient’s total risk of nonfatal and fatal cardiovascular events after an acute coronary syndrome (ACS).

A study of Native Americans who experienced ischemic stroke showed they carried a high burden of risk factors, nearly all of which grew in prevalence from 2000 to 2016.

A projected increase in extreme weather driven by climate change could have a lasting effect on expectant mothers and their children, according to a study that recently linked maternal heat exposure to an elevated risk of congenital heart defects (CHDs) in the U.S.

Direct oral anticoagulants (DOACs) are on their way to surpassing warfarin as the anticoagulant of choice among Medicaid beneficiaries, despite their higher cost, according to new research published in the Journal of the American College of Cardiology.

Cancer patients who experienced tachycardia within one year of being diagnosed carried higher mortality rates up to a decade later—even after adjusting for clinical characteristics and medication use—according to research presented Jan. 25 at the Advancing the Cardiovascular Care of the Oncology Patient conference.

Breast cancer patients under 60 years old are nearly twice as likely as their healthy counterparts to develop both short- and long-term atrial fibrillation (AF), researchers reported Jan. 29 in Heart Rhythm.

A new analysis published in the Journal of the American College of Cardiology suggests the learning curve for achieving the best transcatheter aortic valve replacement (TAVR) outcomes may have dissipated with a current-generation, balloon-expandable device.